{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:44:34Z","timestamp":1794321874186,"version":"4.9.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["CB07\/08\/0037"],"award-info":[{"award-number":["CB07\/08\/0037"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Government of Catalonia","doi-asserted-by":"publisher","award":["2017 SGR 1508"],"award-info":[{"award-number":["2017 SGR 1508"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Government of Catalonia","doi-asserted-by":"publisher","award":["2021 SGR 01012"],"award-info":[{"award-number":["2021 SGR 01012"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["FPU2014-FPU14\/05268"],"award-info":[{"award-number":["FPU2014-FPU14\/05268"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["BES-2015-075799"],"award-info":[{"award-number":["BES-2015-075799"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["FPU2012-FPU12\/03589"],"award-info":[{"award-number":["FPU2012-FPU12\/03589"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PRE2018-084309"],"award-info":[{"award-number":["PRE2018-084309"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003741","name":"Instituci\u00f3 Catalana de Recerca i Estudis Avan\u00e7ats","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003741","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Spain Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["FPU2012-FPU12\/03589"],"award-info":[{"award-number":["FPU2012-FPU12\/03589"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Spain Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["SAF2017-86266R"],"award-info":[{"award-number":["SAF2017-86266R"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Spain Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["FPU2014-FPU14\/05268"],"award-info":[{"award-number":["FPU2014-FPU14\/05268"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Spain Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["PRE2018-084309"],"award-info":[{"award-number":["PRE2018-084309"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Spain Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["BES-2015-075799"],"award-info":[{"award-number":["BES-2015-075799"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ymthe.2024.10.023","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T03:06:00Z","timestamp":1730257560000},"page":"4285-4302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapy"],"prefix":"10.1016","volume":"32","author":[{"given":"Veronica","family":"Jimenez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Sacristan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Jambrina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Jaen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefania","family":"Casana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Marc\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Molas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignasi","family":"Grass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivet","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Vil\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Casellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tura","family":"Ferre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rod\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Carretero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marti","family":"Pumarola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Andaluz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"A\u00f1or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Franckhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assumpta","family":"Caix\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7705-5515","authenticated-orcid":false,"given":"Fatima","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.10.023_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.endmts.2021.100089","article-title":"The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors\u2013A targeted literature review","volume":"3","author":"Dufour","year":"2021","journal-title":"Endocr. Metab. Sci."},{"key":"10.1016\/j.ymthe.2024.10.023_bib2","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2024.10.023_bib3","doi-asserted-by":"crossref","first-page":"13219","DOI":"10.3390\/ijms222413219","article-title":"The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease","volume":"22","author":"Filipovic","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.10.023_bib4","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2024.10.023_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003100","article-title":"Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies","volume":"17","author":"Jarvis","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.ymthe.2024.10.023_bib6","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4158\/EP-2019-0342","article-title":"Impact of type 2 diabetes on nonalcoholic steatohepatitis and advanced fibrosis in patients with nonalcoholic fatty liver disease","volume":"26","author":"Bian","year":"2020","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.ymthe.2024.10.023_bib7","article-title":"Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study","volume":"2","author":"O\u2019Hara","year":"2020","journal-title":"JHEP Rep."},{"key":"10.1016\/j.ymthe.2024.10.023_bib8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/d41573-024-00051-1","article-title":"NASH field celebrates \u2018hurrah moment\u2019 with a first FDA drug approval for the liver disease","volume":"23","author":"Kingwell","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.10.023_bib9","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease."},{"key":"10.1016\/j.ymthe.2024.10.023_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.10.023_bib11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.10.023_bib12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current Clinical Applications of In\u00a0Vivo Gene Therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.10.023_bib13","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1089\/hum.2015.158","article-title":"Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis","volume":"27","author":"Gaudet","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.10.023_bib14","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ymthe.2017.03.029","article-title":"5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency","volume":"25","author":"Mueller","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.10.023_bib15","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2011-09-382317","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.10.023_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2017.03.008","article-title":"Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs","volume":"6","author":"Ja\u00e9n","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.10.023_bib17","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/db12-1113","article-title":"Treatment of diabetes and long-term survival after insulin and glucokinase gene therapy","volume":"62","author":"Callejas","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.ymthe.2024.10.023_bib18","article-title":"Fibroblast growth factor 21: An emerging pleiotropic regulator of lipid metabolism and the metabolic network","volume":"11","author":"Li","year":"2024","journal-title":"Genes Dis."},{"key":"10.1016\/j.ymthe.2024.10.023_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/TCRM.S352008","article-title":"Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease","volume":"19","author":"Raptis","year":"2023","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ymthe.2024.10.023_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101152","article-title":"FGF19 and FGF21: In NASH we trust","volume":"46","author":"Talukdar","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.ymthe.2024.10.023_bib21","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708791","article-title":"FGF21 gene therapy as treatment for obesity and insulin resistance","volume":"10","author":"Jimenez","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2024.10.023_bib22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1089\/hum.2020.29117.trf","article-title":"Revisiting the \u201cNew\u201d Inflammatory Toxicities of Adeno-Associated Virus Vectors","volume":"31","author":"Flotte","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.10.023_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1001263","article-title":"rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.10.023_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.10.023_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.10.023_bib26","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.10.023_bib27","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1016\/j.ymthe.2021.10.024","article-title":"Topics in AAV integration come front and center at ASGCT AAV Integration Roundtable","volume":"29","author":"Sabatino","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.10.023_bib28","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.10.023_bib29","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1016\/j.vaccine.2016.10.053","article-title":"Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques","volume":"34","author":"Greig","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2024.10.023_bib30","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1089\/hum.2011.053","article-title":"Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing \u03b11-antitrypsin: interim results","volume":"22","author":"Flotte","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.10.023_bib31","doi-asserted-by":"crossref","first-page":"16363","DOI":"10.1073\/pnas.0904514106","article-title":"Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy","volume":"106","author":"Brantly","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.10.023_bib32","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1089\/hum.2023.119","article-title":"Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors","volume":"34","author":"Costa-Verdera","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.10.023_bib33","doi-asserted-by":"crossref","first-page":"21240","DOI":"10.3390\/ijms141121240","article-title":"Lessons from mouse models of high-fat diet-induced NAFLD","volume":"14","author":"Nakamura","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.10.023_bib34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2024.10.023_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","article-title":"Hepatic stellate cells as key target in liver fibrosis","volume":"121","author":"Higashi","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2024.10.023_bib36","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1073\/pnas.0701600104","article-title":"BetaKlotho is required for metabolic activity of fibroblast growth factor 21","volume":"104","author":"Ogawa","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.10.023_bib37","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1093\/hmg\/ddp236","article-title":"Diet-induced hepatocellular carcinoma in genetically predisposed mice","volume":"18","author":"Hill-Baskin","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2024.10.023_bib38","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.3390\/cancers13164091","article-title":"Dietary and Genetic Cholesterol Loading Rather Than Steatosis Promotes Liver Tumorigenesis and NASH-Driven HCC","volume":"13","author":"Ribas","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2024.10.023_bib39","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199602013340503","article-title":"Serum immunoreactive-leptin concentrations in normal-weight and obese humans","volume":"334","author":"Considine","year":"1996","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.10.023_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.154028","article-title":"Adiponectin and leptin in the diagnosis and therapy of NAFLD","volume":"103","author":"Boutari","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.ymthe.2024.10.023_bib41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.tins.2017.02.005","article-title":"Obesity-Induced Neuroinflammation: Beyond the Hypothalamus","volume":"40","author":"Guillemot-Legris","year":"2017","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ymthe.2024.10.023_bib42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s40211-019-0302-9","article-title":"Obesity and anxiety symptoms: a systematic review and meta-analysis","volume":"33","author":"Amiri","year":"2019","journal-title":"Neuropsychiatr."},{"key":"10.1016\/j.ymthe.2024.10.023_bib43","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/ijo.2017.81","article-title":"Obesity-induced decreases in muscle performance are not reversed by weight loss","volume":"41","author":"Seebacher","year":"2017","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ymthe.2024.10.023_bib44","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1113\/JP271691","article-title":"\u201cAdipaging\u201d: ageing and obesity share biological hallmarks related to a dysfunctional adipose tissue","volume":"594","author":"P\u00e9rez","year":"2016","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.ymthe.2024.10.023_bib45","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.943417","article-title":"From Liver to Brain: How MAFLD\/MASLD Impacts Cognitive Function","volume":"30","author":"Medina-Julio","year":"2024","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ymthe.2024.10.023_bib46","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.peptides.2007.10.007","article-title":"The fasting polypeptide FGF21 can enter brain from blood","volume":"28","author":"Hsuchou","year":"2007","journal-title":"Peptides (N.Y.)"},{"key":"10.1016\/j.ymthe.2024.10.023_bib47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/17512433.2017.1293521","article-title":"Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications","volume":"10","author":"Hamed","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.10.023_bib48","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.3390\/ijms23095202","article-title":"Obesity as a Risk Factor for Dementia and Alzheimer\u2019s Disease: The Role of Leptin","volume":"23","author":"Flores-Cordero","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.10.023_bib49","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.brainresbull.2012.08.003","article-title":"Metabolic syndrome, mild cognitive impairment and Alzheimer\u2019s disease--the emerging role of systemic low-grade inflammation and adiposity","volume":"89","author":"Misiak","year":"2012","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ymthe.2024.10.023_bib50","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mce.2015.09.018","article-title":"Fibroblast growth factor-21, energy balance and obesity","volume":"418","author":"Giralt","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ymthe.2024.10.023_bib51","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.molmet.2018.03.002","article-title":"Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet","volume":"13","author":"Singhal","year":"2018","journal-title":"Mol. Metab."},{"key":"10.1016\/j.ymthe.2024.10.023_bib52","first-page":"1011","article-title":"Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice","volume":"6","author":"Liu","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.10.023_bib53","first-page":"1762","article-title":"Loss of FGF21 in diabetic mouse during hepatocellular carcinogenetic transformation","volume":"5","author":"Zhang","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.10.023_bib54","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/mc.20241","article-title":"Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis","volume":"45","author":"Huang","year":"2006","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ymthe.2024.10.023_bib55","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1007\/s10620-015-3711-z","article-title":"Long-Term Administration of Fibroblast Growth Factor 21 Prevents Chemically-Induced Hepatocarcinogenesis in Mice","volume":"60","author":"Xu","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ymthe.2024.10.023_bib56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/13543784.2020.1708898","article-title":"Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis","volume":"29","author":"Verzijl","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ymthe.2024.10.023_bib57","article-title":"Pegozafermin Is a Potential Master Therapeutic Regulator in Metabolic Disorders: A Review","author":"Bailey","year":"2023","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.ymthe.2024.10.023_bib58","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/13543784.2023.2230115","article-title":"Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)","volume":"32","author":"Puengel","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ymthe.2024.10.023_bib59","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/osp4.420","article-title":"Weight loss and persistence with liraglutide 3.0\u00a0mg by obesity class in the real-world effectiveness study in Canada","volume":"6","author":"Wharton","year":"2020","journal-title":"Obes. Sci. Pract."},{"key":"10.1016\/j.ymthe.2024.10.023_bib60","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.diabres.2018.07.017","article-title":"Persistence of newer anti-obesity medications in a real-world setting","volume":"143","author":"Ganguly","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ymthe.2024.10.023_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002517","article-title":"Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK","volume":"10","author":"Weiss","year":"2022","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.ymthe.2024.10.023_bib62","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2147\/PPA.S277676","article-title":"Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States","volume":"14","author":"Weiss","year":"2020","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.ymthe.2024.10.023_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065763","article-title":"LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys","volume":"8","author":"Adams","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.10.023_bib64","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1210\/en.2016-1917","article-title":"A novel Fc-FGF21 with improved resistance to proteolysis, increased affinity toward \u03b2-klotho, and enhanced efficacy in mice and cynomolgus monkeys","volume":"158","author":"Stanislaus","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.ymthe.2024.10.023_bib65","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 Analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.ymthe.2024.10.023_bib66","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.ymthe.2024.10.023_bib67","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/dom.13023","article-title":"Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates","volume":"19","author":"Kim","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ymthe.2024.10.023_bib68","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2024.10.023_bib69","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","article-title":"Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2024.10.023_bib70","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1124\/jpet.123.001618","article-title":"The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers","volume":"387","author":"Rosenstock","year":"2023","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ymthe.2024.10.023_bib71","article-title":"A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis","volume":"5","author":"Harrison","year":"2023","journal-title":"JHEP Rep."},{"key":"10.1016\/j.ymthe.2024.10.023_bib72","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.10.023_bib73","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2024.10.023_bib74","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.10.023_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.7","article-title":"Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice","volume":"2","author":"Falk","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.10.023_bib76","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1038\/s41467-021-26744-4","article-title":"Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates","volume":"12","author":"Costa-Verdera","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.10.023_bib77","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.10.023_bib78","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.ymthe.2024.10.023_bib79","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/gt.2009.157","article-title":"High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency","volume":"17","author":"Ayuso","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.10.023_bib80","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1172\/JCI66778","article-title":"Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy","volume":"123","author":"Haurigot","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.10.023_bib81","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1038\/nprot.2013.155","article-title":"Object recognition test in mice","volume":"8","author":"Leger","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2024.10.023_bib82","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0009-9120(93)90015-X","article-title":"Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts","volume":"26","author":"Carr","year":"1993","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ymthe.2024.10.023_bib83","first-page":"1","article-title":"A Systematic Review and Meta-Analysis of Serum Adiponectin Measurements in the Framework of Dog Obesity","volume":"10","author":"Mu\u00f1oz-Prieto","year":"2020","journal-title":"Animals (Basel)"},{"key":"10.1016\/j.ymthe.2024.10.023_bib84","first-page":"279","article-title":"Validation of 2 commercially available enzyme-linked immunosorbent assays for adiponectin determination in canine serum samples","volume":"74","author":"Tvarijonaviciute","year":"2010","journal-title":"Can J. Vet. Res."},{"key":"10.1016\/j.ymthe.2024.10.023_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178436","article-title":"Conophylline inhibits non-alcoholic steatohepatitis in mice","volume":"12","author":"Nakade","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.10.023_bib86","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s00125-010-1840-7","article-title":"Chronically increased glucose uptake by adipose tissue leads to lactate production and improved insulin sensitivity rather than obesity in the mouse","volume":"53","author":"Munoz","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.ymthe.2024.10.023_bib87","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00125-011-2070-3","article-title":"In\u00a0vivo genetic engineering of murine pancreatic beta cells mediated by single-stranded adeno-associated viral vectors of serotypes 6, 8 and 9","volume":"54","author":"Jimenez","year":"2011","journal-title":"Diabetologia"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162400683X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162400683X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:07:04Z","timestamp":1778616424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162400683X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":87,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S152500162400683X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.10.023","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}